Cited by 377Lipid metabolism and disordersLipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index.

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

Graham, Mark J., Lee, Richard G., Bell, Thomas A., Fu, Wuxia, Mullick, Adam E., Alexander, Veronica J., Singleton, Walter, Viney, Nick, Geary, Richard, Su, John, Baker, Brenda F., Burkey, Jennifer, Crooke, Stanley T., Crooke, Rosanne M.·2013·Circulation Research

DOI 10.1161/circresaha.111.300367

Open this paper in CoChat — free account

Abstract

Rationale: Elevated plasma triglyceride levels have been recognized as a risk factor for the development of coronary heart disease. Apolipoprotein C-III (apoC-III) represents both an independent risk factor and a key regulatory factor of plasma triglyceride concentrations. Furthermore, elevated apoC-III levels have been associated with metabolic syndrome and type 2 diabetes mellitus. To date, no selective apoC-III therapeutic agent has been evaluated in the clinic. Objective: To test the hypothesis that selective inhibition of apoC-III with antisense drugs in preclinical models and in healthy volunteers would reduce plasma apoC-III and triglyceride levels. Methods and Results: Rodent- and human-specific second-generation antisense oligonucleotides were identified and evaluated in preclinical models, including rats, mice, human apoC-III transgenic mice, and nonhuman primates. We demonstrated the selective reduction of both apoC-III and triglyceride in all preclinical pharmacological evaluations. We also showed that inhibition of apoC-III was well tolerated and not associated with increased liver triglyceride deposition or hepatotoxicity. A double-blind, placebo-controlled, phase I clinical study was performed in healthy subjects. Administration of the human apoC-III antisense drug resulted in dose-dependent reductions in plasma apoC-III, concomitant lowering of triglyceride levels, and produced no clinically meaningful signals in the safety evaluations. Conclusions: Antisense inhibition of apoC-III in preclinical models and in a phase I clinical trial with healthy subjects produced potent, selective reductions in plasma apoC-III and triglyceride, 2 known risk factors for cardiovascular disease. This compelling pharmacological profile supports further clinical investigations in hypertriglyceridemic subjects.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/circresaha.111.300367

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Ethical principles for medical research involving human subjects
Eckstein, S. (2003) · Cambridge University Press eBooks · doi:10.1017/cbo9780511550089.027 · Cited by 2,592
World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects
Available, N. (2000) · JAMA · doi:10.1001/jama.284.23.3043 · Cited by 2,344
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Lipoprotein lipase: from gene to obesity
Wang, H., & Eckel, R. H. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90920.2008 · Cited by 741
A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection
Pollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688
Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts
Carr, T. P., Andresen, C. J., & Rudel, L. L. (1993) · Clinical Biochemistry · doi:10.1016/0009-9120(93)90015-x · Cited by 558
VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial
Sacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.16.1886 · Cited by 490
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia
Johansen, C. T., Wang, J., Lanktree, M. B., Cao, H., McIntyre, A. D., Ban, M. R., Martins, R. A., Kennedy, B. A., Hassell, R. G., Visser, M. E., et al. (2010) · Nature Genetics · doi:10.1038/ng.628 · Cited by 437

Show all 71 references

Research works printed but not linked: 1

10.1194/jlr.M900346-JLR200 · DOI

Sorted by citations

Items 101–200 of 377

ApoCIII as a cardiovascular risk factor and modulation by the novel lipid-lowering agent volanesorsen
Rocha, N. A., East, C., Zhang, J., & McCullough, P. A. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0697-3 · Cited by 54
Dissecting the Mechanisms Underlying Unusually Successful Human Health Span and Life SpanPreprint
Milman, S., & Barzilai, N. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025098 · Cited by 53
An Overview of the New Frontiers in the Treatment of Atherogenic Dyslipidemias
Rached, F. H., Chapman, M. J., & Kontush, A. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.85 · Cited by 55
Human genetics of HDL: Insight into particle metabolism and function
Brunham, L. R., & Hayden, M. R. (2015) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.01.001 · Cited by 54
Apolipoprotein C-II: the re-emergence of a forgotten factor
Wolska, A. T., Reimund, M., & Remaley, A. T. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000680 · Cited by 58
CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery
Papp, T. E., Zeng, J., Shahnawaz, H., Akyianu, A., Breda, L., Yadegari, A., Steward, J., Shi, R., Li, Q., Mui, B. L., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.018 · Cited by 59
The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism
Luo, M., & Peng, D. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0352-y · Cited by 56
Assessing single-stranded oligonucleotide drug-induced effects in vitro reveals key risk factors for thrombocytopenia
Sewing, S., Roth, A. B., Winter, M., Dieckmann, A., Bertinetti-Lapatki, C., Tessier, Y., McGinnis, C., Huber, S., Koller, E., Ploix, C., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187574 · Cited by 52
Synergistic effect of phosphorothioate, 5′-vinylphosphonate and GalNAc modifications for enhancing activity of synthetic siRNA
Prakash, T. P., Kinberger, G. A., Murray, H. M., Chappell, A. E., Riney, S., Graham, M. J., Lima, W. F., Swayze, E. E., & Seth, P. P. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.04.063 · Cited by 52
Self-citation
Antisense Oligonucleotides: Treatment Strategies and Cellular Internalization
Miller, C. M., & Harris, E. N. (2016) · RNA & DISEASE · doi:10.14800/rd.1393 · Cited by 51
ApoCIII: A multifaceted protein in cardiometabolic disease
D’Erasmo, L., Costanzo, A. D., Gallo, A., Bruckert, É., & Arca, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154395 · Cited by 52
Spotlight on very-low-density lipoprotein as a driver of cardiometabolic disorders: Implications for disease progression and mechanistic insights
Lee, H., Akhmedov, A. T., & Chen, C. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.993633 · Cited by 51
A Novel Apolipoprotein C-II Mimetic Peptide That Activates Lipoprotein Lipase and Decreases Serum Triglycerides in Apolipoprotein E–Knockout Mice
Amar, M. J., Sakurai, T., Sakurai-Ikuta, A., Sviridov, D. O., Freeman, L. A., Ahsan, L., & Remaley, A. T. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.220418 · Cited by 51
Updates on apolipoprotein CIII
Zheng, C. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000040 · Cited by 51
The Association of Human Apolipoprotein C-III Sialylation Proteoforms with Plasma Triglycerides
Yassine, H. N., Trenchevska, O., Ramrakhiani, A., Parekh, A., Koška, J., Walker, R. W., Billheimer, D. D., Reaven, P. D., Yen, F. T., Nelson, R. W., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144138 · Cited by 51
Hypertriglyceridemia and Atherosclerosis: Using Human Research to Guide Mechanistic Studies in Animal Models
Basu, D., & Bornfeldt, K. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00504 · Cited by 51
The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study
Arca, M., Hsieh, A., Soran, H., Rosenblit, P., O’Dea, L., & Stevenson, M. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1487290 · Cited by 49
Inflammatory Links Between Hypertriglyceridemia and Atherogenesis
Peng, X., & Wu, H. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01006-w · Cited by 51
Remnant cholesterol and atherosclerotic cardiovascular disease: Metabolism, mechanism, evidence, and treatment
Wang, K., Wang, R., Yang, J., Liu, X., Shen, H., Sun, Y., Zhou, Y., Fang, Z. A., & Ge, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.913869 · Cited by 49
Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides
Wada, S., Yasuhara, H., Wada, F., Sawamura, M., Waki, R., Yamamoto, T., Harada‐Shiba, M., & Obika, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.007 · Cited by 49
The Medicinal Chemistry of Artificial Nucleic Acids and Therapeutic Oligonucleotides
Bege, M., & Borbás, A. (2022) · Pharmaceuticals · doi:10.3390/ph15080909 · Cited by 51
APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia
Prohaska, T. A., Alexander, V. J., Karwatowska‐Prokopczuk, E., Tami, J. A., Xia, S., Witztum, J. L., & Tsimikas, S. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.04.007 · Cited by 48
Self-citation
Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options
Berman, A. N., & Blankstein, R. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1175-z · Cited by 48
Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms
Trenchevska, O., Schaab, M. R., Nelson, R. W., & Nedelkov, D. (2015) · Methods · doi:10.1016/j.ymeth.2015.02.020 · Cited by 47
Unlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targets
Chen, J., Fang, Z., Luo, Q., Wang, X., Warda, M., Das, A., Oldoni, F., & Luo, F. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-023-01993-y · Cited by 47
Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
Moon, J. H., Kim, K., & Choi, S. H. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.402 · Cited by 53
Antisense oligonucleotides selectively suppress target RNA in nociceptive neurons of the pain system and can ameliorate mechanical pain
Mohan, A., Fitzsimmons, B., Zhao, H. T., Jiang, Y., Mazur, C., Swayze, E. E., & Kordasiewicz, H. B. (2017) · Pain · doi:10.1097/j.pain.0000000000001074 · Cited by 54
Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1BRx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes
DIGENIO, A. G., Pham, N. C., Watts, L. M., Morgan, E. S., Jung, S. W., Baker, B. F., Geary, R. S., & Bhanot, S. (2018) · Diabetes Care · doi:10.2337/dc17-2132 · Cited by 46
Self-citation
Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome
Chaudhry, R., Viljoen, A., & Wierzbicki, A. S. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1480368 · Cited by 47
Injection site reactions after subcutaneous oligonucleotide therapy
van Meer, L., Moerland, M., Gallagher, J., van Doorn, M. B. A., Prens, E. P., Cohen, A. F., Rissmann, R., & Burggraaf, J. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12961 · Cited by 45
PSD3 downregulation confers protection against fatty liver disease
Mancina, R. M., Sasidharan, K., Lindblom, A., Wei, Y., Ciociola, E., Jamialahmadi, O., Pingitore, P., Andréasson, A., Pellegrini, G., Baselli, G., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-021-00518-0 · Cited by 45
Self-citation
Novel therapeutics in hypertriglyceridemia
Gryn, S. E., & Hegele, R. A. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000231 · Cited by 44
Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial
Witztum, J. L., Gaudet, D., Arca, M., Jones, A., Soran, H., Gouni‐Berthold, I., Stroes, E. S. G., Alexander, V. J., Jones, R., Watts, L. M., et al. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.03.007 · Cited by 45
Self-citation
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I. M., Backer, G. D., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0157 · Cited by 48
Inulin Improves Postprandial Hypertriglyceridemia by Modulating Gene Expression in the Small Intestine
Hiel, S., Neyrinck, A. M., Rodriguez, J., Pachikian, B. D., Bouzin, C., Thissen, J., Cani, P. D., Bindels, L. B., & Delzenne, N. M. (2018) · Nutrients · doi:10.3390/nu10050532 · Cited by 41
New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?
Olkkonen, V. M., Sinisalo, J. P., & Jauhiainen, M. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.019 · Cited by 41
The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia
Gouni‐Berthold, I. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.003 · Cited by 40
Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits
Yan, H., Niimi, M., Matsuhisa, F., Zhou, H., Kitajima, S., Chen, Y., Wang, C., Yang, X., Yao, J. Q., Yang, D., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314368 · Cited by 39
The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation
Sundaram, M., Curtis, K. R., Alipour, M. A., LeBlond, N. D., Margison, K. D., Yaworski, R., Parks, R. J., McIntyre, A. D., Hegele, R. A., Fullerton, M. D., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m077313 · Cited by 40
Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia
Nurmohamed, N. S., Dallinga‐Thie, G. M., & Stroes, E. S. G. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1768848 · Cited by 42
Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia
Renee Ruhaak, L., van der Laarse, A., & Cobbaert, C. M. (2019) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563219827620 · Cited by 38
Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs
Baylot, V., Le, T. K., Taïeb, D., Rocchi, P., & Colleaux, L. (2024) · Communications Biology · doi:10.1038/s42003-024-06121-9 · Cited by 44
Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors
Tomlinson, B., Wu, Q., Zhong, Y.-M., & Li, Y. (2024) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2024.13.1.2 · Cited by 39
Targeting angiotensinogen with RNA-based therapeutics
Ren, L., Colafella, K. M. M., Bovée, D. M., Uijl, E., & Danser, A. H. J. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000586 · Cited by 38
The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?
Reeskamp, L. F., Tromp, T. R., & Stroes, E. S. G. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000679 · Cited by 40
Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies
Dib, I., Khalil, A., Chouaib, R., El-Makhour, Y., & Noureddine, H. (2021) · Molecular Biology Reports · doi:10.1007/s11033-020-06071-5 · Cited by 37
New Drugs for Atherosclerosis
Bruikman, C. S., Stoekenbroek, R. M., Hovingh, G. K., & Kastelein, J. J. P. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.09.010 · Cited by 38
APOC3 siRNA and ASO therapy for dyslipidemia
Chebli, J., Larouche, M., & Gaudet, D. (2024) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000857 · Cited by 35
Rare Variant APOC3 R19X Is Associated With Cardio-Protective Profiles in a Diverse Population-Based Survey as Part of the Epidemiologic Architecture for Genes Linked to Environment Study
Crawford, D. C., Dumitrescu, L. C., Goodloe, R., Brown-Gentry, K. D., Boston, J., McClellan, B., Sutcliffe, C. B., Wiseman, R., Baker, P. G., Pericak‐Vance, M. A., et al. (2014) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.113.000369 · Cited by 36
The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease
Gabani, M. H., Shapiro, M. D., & Toth, P. P. (2023) · European Cardiology Review · doi:10.15420/ecr.2023.16 · Cited by 40
Rethinking HDL-C: An In-Depth Narrative Review of Its Role in Cardiovascular Health
Perswani, P., Ismail, S. M., Mumtaz, H., Uddin, N., Asfand, M., Khalil, A. B. B., Ijlal, A., Khan, S. E., Usman, M. A., Younas, H., et al. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102152 · Cited by 36
A review of animal models utilized in preclinical studies of approved gene therapy products: trends and insights
Soufizadeh, P., Mansouri, V., & Ahmadbeigi, N. (2024) · Laboratory Animal Research · doi:10.1186/s42826-024-00195-6 · Cited by 43
Targeting ApoC-III to Reduce Coronary Disease Risk
Khetarpal, S. A., Qamar, A., Millar, J. S., & Rader, D. J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0609-y · Cited by 34
Personalized Management of Cardiovascular Disorders
Jain, K. K. (2017) · Medical Principles and Practice · doi:10.1159/000481403 · Cited by 37
Antisense antibacterial compounds
Pifer, R., & Greenberg, D. E. (2020) · Translational research · doi:10.1016/j.trsl.2020.06.001 · Cited by 34
Volanesorsen: A New Era in the Treatment of Severe Hypertriglyceridemia
Kolovou, G., Kolovou, V., & Katsiki, N. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040982 · Cited by 33
A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD
Srivastava, R. A. K. (2023) · Cells · doi:10.3390/cells12121648 · Cited by 40
Association of Triglyceride-Related Genetic Variants With Mitral Annular Calcification
Afshar, M. S., Luk, K., Do, R., Dufresne, L., Owens, D. S., Harris, T. B., Peloso, G. M., Kerr, K. F., Wong, Q., Smith, A. V., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.051 · Cited by 33
Therapeutic targets of triglyceride metabolism as informed by human genetics
Bauer, R. C., Khetarpal, S. A., Hand, N. J., & Rader, D. J. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.02.005 · Cited by 32
Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial
Bays, H. E., Hallén, J., Vige, R., Fraser, D. A., Zhou, R., Hustvedt, S. O., Orloff, D. G., & Kastelein, J. J. P. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.10.012 · Cited by 32
Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia
Wierzbicki, A. S., & Viljoen, A. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1196182 · Cited by 32
Increased inflammation, endoplasmic reticulum stress and oxidative stress in endothelial and macrophage cells exacerbate atherosclerosis in ApoCIII transgenic mice
Yingchun, H., Ma, Y., Wen, J., He, X., & Xiaohong, Z. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0867-5 · Cited by 35
Causes, clinical findings and therapeutic options in chylomicronemia syndrome, a special form of hypertriglyceridemia
Paragh, G., Németh, Á., Harangi, M., Banach, M., & Fülöp, P. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01631-z · Cited by 35
The effect of omega-3 carboxylic acids on apolipoprotein CIII−containing lipoproteins in severe hypertriglyceridemia
Morton, A. M., Furtado, J. D., Lee, J., Amerine, W., Davidson, M. H., & Sacks, F. M. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.09.005 · Cited by 32
Prognostic utility of triglyceride-rich lipoprotein-related markers in patients with coronary artery disease
Cao, Y., Zhang, H., Jin, J., Liu, H., Zhang, Y., Xu, R., Gao, Y., Guo, Y., Zhu, C., Hua, Q., et al. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra120000746 · Cited by 31
Antisense Oligonucleotides as Potential Therapeutics for Type 2 Diabetes
Chen, S., Sbuh, N., & Veedu, R. N. (2020) · Nucleic Acid Therapeutics · doi:10.1089/nat.2020.0891 · Cited by 30
Guanidinylated Apolipoprotein C3 (ApoC3) Associates with Kidney and Vascular Injury
Schunk, S. J., Hermann, J., Sarakpi, T., Triem, S., Lellig, M., Hahm, E., Zewinger, S., Schmit, D., Becker, E., Möllmann, J., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021040503 · Cited by 31
Lomitapide for the treatment of hypertriglyceridemia
Berberich, A. J., & Hegele, R. A. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1254187 · Cited by 29
Down-regulation of the liver-derived plasma protein fetuin-B mediates reversible female infertility
Floehr, J., Dietzel, E., Schmitz, C., Chappell, A. E., & Jahnen‐Dechent, W. (2016) · Molecular Human Reproduction · doi:10.1093/molehr/gaw068 · Cited by 29
The Remnants of Residual Risk∗
Joshi, P. H., Martin, S. S., & Blumenthal, R. S. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.543 · Cited by 29
Oligonucleotide-Based Therapies for Chronic HBV Infection: A Primer on Biochemistry, Mechanisms and Antiviral Effects
Vaillant, A. (2022) · Viruses · doi:10.3390/v14092052 · Cited by 30
DNA and RNA derivatives to optimize distribution and delivery
Wickstrom, E. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.04.012 · Cited by 28
RNA-based therapy in the management of lipid disorders: a review
Blom, D. J., Marais, A. D., Moodley, R., van der Merwe, N., van Tonder, A., & Raal, F. J. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01649-3 · Cited by 29
Apolipoproteins as potential communicators play an essential role in the pathogenesis and treatment of early atherosclerosis
Yang, L., Luo, X., Hua, Z., Xue, X., Wang, X., Pang, M., Wang, T., Lü, A., & Liu, Y. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.86475 · Cited by 30
Metabolic Characterization of a Rare Genetic Variation Within APOC3 and Its Lipoprotein Lipase–Independent Effects
Drenos, F., Smith, G. D., Ala‐Korpela, M., Kettunen, J., Würtz, P., Soininen, P., Kangas, A. J., Dale, C. E., Lawlor, D. A., Gaunt, T. R., et al. (2016) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.115.001302 · Cited by 26
Very low-depth sequencing in a founder population identifies a cardioprotectiveAPOC3signal missed by genome-wide imputation
Gilly, A., Ritchie, G. R. S., Southam, L., Farmaki, A., Tsafantakis, E., Dedoussis, G. V., & Zeggini, E. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw088 · Cited by 27
Deletion of Lymphangiogenic and Angiogenic Growth Factor VEGF-D Leads to Severe Hyperlipidemia and Delayed Clearance of Chylomicron Remnants
Tirronen, A., Vuorio, T., Kettunen, S., Hokkanen, K., Ramms, B., Niskanen, H., Laakso, H., Kaikkonen, M. U., Jauhiainen, M., Gordts, P. L. S. M., et al. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311549 · Cited by 26
Lack of Interactions Between an Antisense Oligonucleotide with 2′- O -(2-Methoxyethyl) Modifications and Major Drug Transporters
Yu, R. Z., Warren, M. S., Watanabe, T. A., Nichols, B., Jahic, M., Huang, J., Burkey, J., Geary, R. S., Henry, S. P., & Wang, Y. (2016) · Nucleic Acid Therapeutics · doi:10.1089/nat.2015.0588 · Cited by 26
Self-citation
Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS)
D’Erasmo, L., Bini, S., & Arca, M. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00967-8 · Cited by 26
Residual cardiovascular risk among people with diabetes
Dash, S., & Leiter, L. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13646 · Cited by 27
Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials
Sahebkar, A., Simental‐Mendía, L. E., Mikhailidis, D. P., Pirro, M., Banach, M., Sirtori, C. R., Ruscica, M., & Reiner, Ž. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.01.008 · Cited by 25
Volanesorsen for treatment of familial chylomicronemia syndrome
Lazarte, J., & Hegele, R. A. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.1955348 · Cited by 25
Monocyte and macrophage foam cells in diabetes-accelerated atherosclerosis
Cervantes, J., & Kanter, J. E. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1213177 · Cited by 24
Inhibition of ApoCIII
Moens, S. J. B., van Capelleveen, J. C., & Stroes, E. S. G. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000130 · Cited by 24
Pharmacological Management of Dyslipidemia in Atherosclerosis: Limitations, Challenges, and New Therapeutic Opportunities
Kypreos, K. E., Bitzur, R., Karavia, E. A., Xepapadaki, E., Panayiotakopoulos, G. D., & Constantinou, C. (2018) · Angiology · doi:10.1177/0003319718779533 · Cited by 26
Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia
D’Erasmo, L., Gallo, A., Costanzo, A. D., Bruckert, É., & Arca, M. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1787380 · Cited by 24
Remnant lipoprotein cholesterol is associated with incident new onset diabetes after transplantation (NODAT) in renal transplant recipients: results of the TransplantLines Biobank and cohort Studies
Szili‐Török, T., Sokooti, S., Osté, M. C. J., Neto, A. W. G., Dullaart, R. P. F., Bakker, S. J. L., & Tietge, U. J. F. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01475-y · Cited by 25
Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism
Deprince, A., Hennuyer, N., Kooijman, S., Pronk, A. C. M., Baugé, E., Liénard, V., Verrijken, A., Dirinck, E. L., Vonghia, L., Woitrain, E., et al. (2022) · Hepatology · doi:10.1002/hep.32631 · Cited by 24
Early-Stage Identification and Avoidance of Antisense Oligonucleotides Causing Species-Specific Inflammatory Responses in Human Volunteer Peripheral Blood Mononuclear Cells
Burel, S. A., Machemer, T., Baker, B. F., Kwoh, T. J., Paz, S., Younis, H. S., & Henry, S. P. (2022) · Nucleic Acid Therapeutics · doi:10.1089/nat.2022.0033 · Cited by 22
Self-citation
Two novel mutations in apolipoprotein C3 underlie atheroprotective lipid profiles in families
Bochem, A. E., van Capelleveen, J. C., Dallinga‐Thie, G. M., Schimmel, A. W. M., Motazacker, M. M., Tietjen, I., Singaraja, R. R., Hayden, M. R., Kastelein, J. J. P., Stroes, E. S. G., et al. (2013) · Clinical Genetics · doi:10.1111/cge.12201 · Cited by 26
Clinical and genetic features of 3 patients with familial chylomicronemia due to mutations in GPIHBP1 gene
Rabacchi, C., D’Addato, S., Palmisano, S., Lucchi, T. A., Bertolini, S., Calandra, S., & Tarugi, P. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.03.009 · Cited by 24
Harnessing nucleic acid-based therapeutics for atherosclerotic cardiovascular disease: state of the art
Vahdat‐Lasemi, F., Mahjoubin‐Tehran, M., Aghaee‐Bakhtiari, S. H., Jalili, A., Jaafari, M. R., & Sahebkar, A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.04.007 · Cited by 24
Translating atherosclerosis research from bench to bedside: navigating the barriers for effective preclinical drug discovery
May, L. T., Bartolo, B. A. D., Harrison, D. G., Guzik, T. J., Drummond, G. R., Figtree, G. A., Ritchie, R. H., Rye, K., & de Haan, J. B. (2022) · Clinical Science · doi:10.1042/cs20210862 · Cited by 23
New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3
Kim, J. Y., & Kim, N. H. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.23 · Cited by 23
Interventional hepatic apoC-III knockdown improves atherosclerotic plaque stability and remodeling by triglyceride lowering
Ramms, B., Patel, S., Sun, X., Pessentheiner, A. R., Ducasa, G. M., Mullick, A. E., Lee, R. G., Crooke, R. M., Tsimikas, S., Witztum, J. L., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.158414 · Cited by 22
Self-citation
PCSK9 and resistin at the crossroads of the atherogenic dyslipidemia
Rashid, S., & Kastelein, J. J. P. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2013.839204 · Cited by 24
Mass Spectrometric Immunoassays for Discovery, Screening and Quantification of Clinically Relevant Proteoforms
Trenchevska, O., Nelson, R. W., & Nedelkov, D. (2016) · Bioanalysis · doi:10.4155/bio-2016-0060 · Cited by 21
Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline: a longitudinal study
Lin, J. J., Khetarpal, S. A., Terembula, K., Reilly, M. P., & Wilson, F. P. (2015) · BMC Nephrology · doi:10.1186/s12882-015-0122-5 · Cited by 22
Prognostic impact of estimated remnant-like particle cholesterol in patients with differing glycometabolic status: an observational cohort study from China
Zhao, Q., Zhang, T., Cheng, Y., Ma, Y., Xu, Y.-K., Yang, J., & Zhou, Y.-J. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01355-y · Cited by 19
Metabolism of Triglyceride-Rich Lipoproteins
Borén, J., & Taskinen, M. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_520 · Cited by 22

Authors: Graham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., Baker, B. F., Burkey, J., Crooke, S. T., & Crooke, R. M.
Affiliations: Ionis Pharmaceuticals (United States) (US)
Corresponding author: Graham, Mark J.
Lee, Richard G.
ORCID: Lee, Richard G.
Mullick, Adam E.
Alexander, Veronica J.
Geary, Richard
Baker, Brenda F.
Crooke, Stanley T.
Venue: Circulation Research
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2013-05-24
Volume: 112
Issue: 11
Pages: 1479-1490
ISSN: 0009-7330 (ISSN-L)
1524-4571
DOI: 10.1161/circresaha.111.300367
OpenAlex: W2170210469
Cited by: 377
References: 71
Citations by year: 2026: 16 · 2025: 14 · 2024: 15 · 2023: 17 · 2022: 31 · 2021: 19 · 2020: 41 · 2019: 31 · 2018: 29 · 2017: 25 · 2016: 45 · 2015: 41 · 2014: 39 · 2013: 12
FWCI: 31.05
Type: journal article
Language: en
Open access: closed
Locations: Circulation Research (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords: apolipoprotein C-III, antisense oligonucleotides, plasma triglycerides, hypertriglyceridemia, triglyceride-lowering therapy, cardiovascular risk factors, type 2 diabetes, metabolic syndrome, hepatotoxicity, non-human primates
MeSH terms: Animals, Double-Blind Method, Humans, Macaca fascicularis, Macaca mulatta, Mice, Inbred C57BL, Oligonucleotides, Placebos, Rats, Zucker, Receptors, LDL, Risk Factors, RNA, Messenger, Triglycerides, Hypertriglyceridemia, Genetic Therapy, Oligonucleotides, Antisense, Mice, Knockout, Mice, Rats, Apolipoprotein C-III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks